BRIEF published on 07/24/2026 at 10:01, 24 days ago BlackRock Inc. reduces its stake in IPSEN SA Voting Rights Actions BlackRock Threshold Crossing Ipsen SA
BRIEF published on 07/24/2026 at 10:01, 24 days ago BlackRock Inc. réduit sa participation dans IPSEN SA Droits De Vote Franchissement De Seuil Actions BlackRock Ipsen SA
PRESS RELEASE published on 07/24/2026 at 09:56, 24 days 1 hour ago Franchissement de seuil BlackRock Inc. declares crossing below 5% threshold in IPSEN SA capital and voting rights on July 6, 2026 Déclaration BlackRock Inc. Threshold Crossing Ipsen SA Capital Decrease
BRIEF published on 07/24/2026 at 07:05, 24 days 3 hours ago Mise à jour sur l'essai BOLD de phase III d'Ipsen dans l'atrésie des voies biliaires Recherche Clinique Odevixibat Atrésie Des Voies Biliaires Essai BOLD De Phase III Transplantation Hépatique
BRIEF published on 07/24/2026 at 07:05, 24 days 3 hours ago Update on Ipsen's Phase III BOLD Trial in Biliary Atresia Clinical Research Biliary Atresia Phase III BOLD Trial Odevixibat Liver Transplantation
PRESS RELEASE published on 07/24/2026 at 07:00, 24 days 3 hours ago Ipsen fait le point sur l'essai de Phase III BOLD dans l'atrésie des voies biliaires Ipsen annonce que l'essai de Phase III BOLD pour l'atrésie des voies biliaires n'a pas atteint son critère principal. Les données confirment le profil de sécurité de l'odévixibat Ipsen Essai De Phase III Odevixibat Atrésie Des Voies Biliaires BOLD
PRESS RELEASE published on 07/24/2026 at 07:00, 24 days 3 hours ago Ipsen provides update on Phase III BOLD trial in biliary atresia Ipsen's Phase III BOLD trial for biliary atresia did not meet primary endpoint. Bylvay safety profile confirmed. Insights gained will aid future research and patient care Ipsen Biliary Atresia Phase III BOLD Trial Bylvay Pediatric Liver Transplant
BRIEF published on 07/09/2026 at 07:05, 1 month 8 days ago Dysport® franchit une étape importante dans les essais de phase III sur la migraine Essais De Phase III Dysport Migraine Épisodique Migraine Chronique Toxine Botulique
BRIEF published on 07/09/2026 at 07:05, 1 month 8 days ago Dysport® Achieves Milestone in Migraine Phase III Trials Phase III Trials Dysport Episodic Migraine Chronic Migraine Botulinum Toxin
BRIEF published on 07/09/2026 at 07:05, 1 month 8 days ago Résultats Positifs en Phase III pour Dysport® dans le Traitement de la Migraine Phase III Dysport Migraine Épisodique Migraine Chronique Toxine Botulinique
Published on 08/17/2026 at 09:10, 1 hour 47 minutes ago HM Exploration Commences Borehole & Surface EM Surveys at Lewis Pilley's
Published on 08/15/2026 at 00:15, 2 days 10 hours ago Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 2 days 11 hours ago AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/17/2026 at 10:35, 21 minutes ago Disclosure according to Article 5(1)(b) of the EU Regulation No. 596/2014 and Article 2(3) of the Delegated EU Regulation No. 2016/1052 - 2nd Interim Report
Published on 08/17/2026 at 10:28, 28 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 08/17/2026 at 10:15, 41 minutes ago CoinShares Digital Securities Limited: EU RIS CSDS Polkadot ETP - Staking Reward Change
Published on 08/17/2026 at 10:15, 41 minutes ago CoinShares Digital Securities Limited: EU RIS CSDS Tezos ETP - Staking Reward Change
Published on 08/17/2026 at 10:05, 51 minutes ago Ensuring Uninterrupted Critical Operations: New Hybrid Technology Bridges Broadband Coverage Gaps
Published on 08/17/2026 at 08:33, 2 hours 24 minutes ago Covivio - Information on Treasury shares transactions between August 10th, 2026 and August 11th, 2026
Published on 08/17/2026 at 08:33, 2 hours 24 minutes ago Covivio - Déclaration des transactions sur actions propres réalisées du 10 août 2026 au 11 août 2026
Published on 08/17/2026 at 07:30, 3 hours 27 minutes ago Déclaration hebdomadaire d'opérations effectuées du 10 au 14 août 2026
Published on 08/17/2026 at 07:30, 3 hours 27 minutes ago Disclosure of transactions in own shares from August 10 to August 14, 2026
